Novo Nordisk (NVO) Reports Q2 EPS of DKK10.17; raises outlook

Novo Nordisk (NYSE: NVO) reported Q2 EPS of DKK10.17. Revenue for the quarter came in at DKK133.41 billion.

OUTLOOK

For the 2024 outlook, sales growth is now expected to be 22-28% at CER, and operating profit growth is now expected to be 20-28% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for both sales and operating profit.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.

You May Also Be Interested In

• Blue Owl Credit Income Corp caps Q2 tender offer at 5% of shares
• Ferrari (RACE) PT Raised to $497 at UBS: Sequential Acceleration Likely in Q2
• Greenbrier Companies (GBX) PT Lowered to $42 at BofA Securities